Key result
LIVER-ASCVD+ model improves MI and stroke risk prediction over standard ASCVD estimator in MASH patients.
Why the study?
Conventional cardiovascular risk models are limited in accurately predicting CVD risk in patients with MASLD/MASH.
Does the LIVER-ASCVD+ model improve predictive accuracy for cardiovascular events and mortality compared to the ASCVD Risk Estimator Plus in patients with MASH?
Cohort (n=9,185)
Does the LIVER-ASCVD+ model improve predictive accuracy for cardiovascular events and mortality compared to the ASCVD Risk Estimator Plus in patients with MASH?
Answers are grounded in this paper and cite their sources.
The LIVER-ASCVD+ model, which integrates liver-specific biomarkers with traditional risk factors, improves the prediction of cardiovascular events and mortality in patients with MASH compared to the standard ASCVD Risk Estimator Plus.
AIM: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), and its more severe form, Metabolic Dysfunction-Associated Steatohepatitis (MASH), pose significant global health challenges. Conventional cardiovascular risk models, such as the ASCVD Risk Estimator Plus, are limited in accurately predicting CVD risk in MASLD/MASH patients. This study aims to enhance the predictive accuracy of cardiovascular events in MASLD/MASH patients by developing a novel regression model, the LIVER-ASCVD+ model, which integrates traditional cardiovascular risk factors with liver biomarkers. METHODS: A retrospective cohort study was conducted using data from 9,185 biopsy-confirmed MASH patients within an integrated delivery network in the US. The study compared the performance of the LIVER-ASCVD+ model against the ASCVD Risk Estimator Plus. Kaplan-Meier survival analysis was conducted to assess outcomes, with comparisons made to two propensity-matched non-MASH control cohorts. RESULTS: The LIVER-ASCVD+ model demonstrated superior predictive accuracy for myocardial infarction (MI)/stroke events (AUC: 0.68) and mortality (AUC: 0.63) compared to the ASCVD Risk Estimator Plus (MI/stroke AUC: 0.63; mortality AUC: 0.54). The model stratified patients into high and low-risk categories, with significant differences observed in 10-year MI/stroke incidence and mortality rates. Kaplan-Meier analyses further validated the improved performance of the LIVER-ASCVD+ model in predicting cardiovascular outcomes. CONCLUSION: The integration of liver-specific biomarkers into cardiovascular risk assessment models for MASLD/MASH patients significantly enhances predictive accuracy. The LIVER-ASCVD+ model represents a promising approach to improving clinical decision-making and patient outcomes in MASLD/MASH, warranting further validation.
No takes yet. Share an insight, caveat, or question.
Hegstrom et al. (2025) conducted a cohort in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (n=9,185). LIVER-ASCVD+ model vs. ASCVD Risk Estimator Plus was evaluated on Predictive accuracy for myocardial infarction (MI)/stroke events (AUC 0.68). The LIVER-ASCVD+ model demonstrated superior predictive accuracy for MI/stroke and mortality compared to the ASCVD Risk Estimator Plus in MASH patients.
Synapse has enriched 10 related papers. Consider them for comparative context: